Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02231697 · ClinicalTrials.gov registry record

A Medical Chart Review of Patients With X-Linked Myotubular Myopathy (XLMTM)

A clinical trial, sponsored by Astellas Gene Therapies.

Completed
Registry status
161
Enrollment target

NCT02231697 is a clinical trial that has completed, run by Astellas Gene Therapies. The registered enrollment target is 161 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02231697 has completed, sponsored by Astellas Gene Therapies.

COMPLETED
Registry status
161 participants
Enrollment target

Study Summary

This retrospective medical chart review (RECENSUS) of approximately 100 XLMTM patients (with a goal to obtain 50 deceased and 20 living records) will provide further knowledge about the clinical manifestations and recorded medical management of XLMTM and potentially inform the design of future therapeutic intervention studies.

Interventions

  • OTHER Non-interventional, retrospective medical chart review

Trial Details

FieldValue
Enrollment Target 161 participants
Start Date 2014-09
Est. Completion 2019-12

Sponsor

Astellas Gene Therapies

7 total trials

What the Registry Record Tells You About NCT02231697

The ClinicalTrials.gov registry entry for NCT02231697 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 161 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Gene Therapies, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Non-interventional, retrospective medical chart review is the first listed.

NCT02231697 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02231697 about?

NCT02231697 is a clinical study titled "A Medical Chart Review of Patients With X-Linked Myotubular Myopathy (XLMTM)". This retrospective medical chart review (RECENSUS) of approximately 100 XLMTM patients (with a goal to obtain 50 deceased and 20 living records) will provide further knowledge about the clinical manifestations and recorded medical management of XLMTM and potentially inform the design of future thera...

What is the current status of trial NCT02231697?

This trial is currently completed. The enrollment target is 161 participants. The study started on 2014-09. Estimated completion is 2019-12.

What interventions are being tested in trial NCT02231697?

The interventions under investigation include: Non-interventional, retrospective medical chart review (OTHER).

Who is sponsoring clinical trial NCT02231697?

This trial is sponsored by Astellas Gene Therapies, which has 7 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.